Graphite Bio has filed to raise up to $100 million in an IPO. The money will support the development of gene editing drugs for sickle cell disease, X-linked severe combined immunodeficiency syndrome ...
The biggest challenge for scientists working on genome engineering, according to Josh Lehrer, M.D., CEO of the newly announced Graphite Bio, is targeting DNA at a specific location and inserting new, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results